Pharmacist Advanced Training Diabetes | Microcredentials On-Demand 6.5 credit hours

The CGM course comprises six comprehensive modules designed to equip pharmacists with essential skills and knowledge to successfully integrate CGM services into their pharmacy. Content includes an in-depth understanding of CGM technology and its benefits, ways to tailor management of suitable candidates for CGM use, practical steps for integrating a CGM service into pharmacy practice, tools and techniques for managing CGM patients remotely, and how CGMs can monitor the impact of nutrition, weight management, physical activity, and wellness activities. Pharmacists will be empowered to develop a sustainable service to improve health outcomes for patients with and without diabetes. 

Continuous Glucose Monitoring (CGM) - Pharmacist

Claim Your Badge

You will receive an email from Credly (our credential partner), after you complete the course, inviting you to claim your digital badge for Continuous Glucose Monitoring (CGM) - Pharmacist. This will allow you to easily share your achievement with colleagues, managers, and your professional network on LinkedIn and other platforms. When you receive the email, please click the button and create an account on Credly.com so that you can “accept” the badge.

Need help? Find a step-by-step tutorial video at this link.

Module 1: CGM System Functionality and Review of Data

Upon successful completion of this module, pharmacists should be able to:
1. Describe current recommendations for the utilization of continuous glucose monitoring (CGM) devices and their significance in diabetes management.
2. Review CGM device components and their functionalities to ensure accurate data collection.
3. Discuss the pros and cons of CGM technology for glycemic management.
4. Explain the metrics provided by CGM devices and their effect on evaluating trends in glycemic management to guide personalized treatment plans for patients.
5. Interpret CGM data to make informed decisions regarding medication dosing, optimization, and diet and lifestyle modifications for individuals with diabetes. 

Module 2: Selection and Management of Patients Using CGM

Upon successful completion of this module, pharmacists should be able to:
1. Compare and contrast commonly available CGMs, including features and capabilities.
2. Evaluate criteria for selecting patients suitable for CGM use in various demographic and health populations.
3. Explain the process of initiating CGM therapy in patients.
4. Discuss common CGM issues to ensure continuous and reliable monitoring.
5. Develop personalized diabetes management plans based on CGM data.

Module 3: CGM Clinical Service Implementation

Upon successful completion of this module, pharmacists should be able to:
1. Discuss the impact of CGM service implementation on patient outcomes and healthcare resource utilization.
2. Recognize motivators and barriers to implementing a CGM service in the pharmacy.
3. Describe procedures for integrating CGM data into routine workflows, including documentation, data review, and collaboration with multidisciplinary care teams.
4. Create an action plan to develop, initiate, and implement a CGM service in the pharmacy.

Module 4: CGM for Remote Patients

Upon successful completion of this module, pharmacists should be able to:
1. Describe the key components, technology, and processes involved in remote patient monitoring (RPM).
2. Identify patient criteria for a successful RPM program.
3. Explain how CGM integrates with telehealth visits and RPM.
4. Discuss pharmacists’ contribution to RPM services, including medication management, patient education, and billing potential.
5. Evaluate a patient case involving the utilization of CGMs in remote patient monitoring.

Module 5: Nutrition and Weight Management for CGM Patients

Upon successful completion of this module, pharmacists should be able to:
1. Review the relationship between dietary patterns, insulin sensitivity, weight management, and metabolic health.
2. Recognize the role of CGMs in providing real-time feedback on the glycemic response to different foods.
3. Identify strategies for optimizing meal timing, macronutrient composition, portion sizes, and meal spacing to minimize glycemic variability.
4. Interpret CGM data to identify patterns of glucose excursions related to specific dietary habits.
5. Recommend nutrition and weight management interventions guided by CGM data in a case scenario.

Module 6: Physical Activity for CGM Patients

Upon successful completion of this module, pharmacists should be able to:
1. Review the relationship between dietary patterns, insulin sensitivity, weight management, and metabolic health.
2. Recognize the role of CGMs in providing real-time feedback on the glycemic response to different foods.
3. Identify strategies for optimizing meal timing, macronutrient composition, portion sizes, and meal spacing to minimize glycemic variability.
4. Interpret CGM data to identify patterns of glucose excursions related to specific dietary habits.
5. Recommend nutrition and weight management interventions guided by CGM data in a case scenario.

Module 7: Prioritizing the Well-Being of CGM Patients

Upon successful completion of this module, pharmacists should be able to:
1. Explain the importance of integrating physical, emotional, and mental well-being into daily routines.
2. Recommend wellness strategies tailored to individual needs and preferences using CGM data.

Faculty

Mark Smith, PharmD, CDCES, AFAA-CGFI

Disclosures:

Mark Smith has no relevant financial relationships with ineligible companies to disclose.

Ian Haywood, PharmD, BCPS, CDCES

Disclosures:

Ian Haywood has no relevant financial relationships with ineligible companies to disclose.

Christie Schumacher, PharmD, BCPS, BCACP, BCCP, BCADM, CDCES, FCCP

Disclosures:

Christie Schumacher is on the advisory board for Novo Nordisk and the speaker’s bureau for Abbott. All relevant financial relationships have been mitigated.

Jennifer N. Clements, PharmD, FCCP, FADCES, BCPS, CDCES, BCACP, BC-ADM

Disclosures:

Jennifer Clements is on the speaker’s bureau for NovoNordisk and Eli Lilly and previous board member for Embecta, as well as a consultant for Xeris Pharmaceuticals. All relevant financial relationships have been mitigated.

Bianca Daisy-Bell, PharmD, BCACP

Disclosures:

Bianca Daisy-Bell has no relevant financial relationships with ineligible companies to disclose.

Nicole Gorsuch, PharmD

Disclosures:

Nicole Gorsuch has no relevant financial relationships with ineligible companies to disclose.

Bridget Dolan Teschke, PharmD, BCACP

Disclosures:

Bridget Dolan Teschke has no relevant financial relationships with ineligible companies to disclose.

Amy Wainright, PharmD, BCACP, BCGP

Disclosures:

Amy Wainright has no relevant financial relationships with ineligible companies to disclose.

Lyndi Mies, MHSc, RDN, LDN

Disclosures:

Lyndi Mies has no relevant financial relationships with ineligible companies to disclose.

Kelly Sklanka, PharmD, CDCES

Disclosures:

Kelly Sklanka has no relevant financial relationships with ineligible companies to disclose.

Bela Patel, PharmD, NBHWC

Disclosures:

Bela Patel has no relevant financial relationships with ineligible companies to disclose.

Course Details